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16) Infection Prevention and Control Department, Imperial College Healthcare NHS Trust, UK
17) Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet and Department of Infectious Diseases, Karolinska University
Hospital, Stockholm, Sweden
18) Unit of Infectious Diseases, Clinical Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena, Institute of Biomedicine of Seville
(I. BIS), Sevilla, Spain
19) Department of Infection Control and Hospital Epidemiology, Medical University of Vienna, Austria
20) Safeguarding Health Through Infection Prevention Research Group, Institute for Applied Health Research, Glasgow Caledonian University, Scotland, UK
21) Infectious Diseases, Research Clinical Unit, DZIF Center, University Hospital Tübingen, Germany
22) Department of Medical Sciences, Uppsala University, Uppsala, Sweden
23) National Reference Center for Surveillance of nosocomial Infections, Charite e Universit€atsmedizin Berlin, Corporate member of Freie Universit€at Berlin
and Humboldt-Universit€at zu Berlin, Institute of Hygiene and Environmental Medicine, Berlin, Germany* This article is part of a supplement entitled Implementing Automated Surveillance of Healthcare-Associated Infections (HAI) sponsored by the PRAISE network (sup-
ported under 7th transnational call within the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), Network Call on Surveillance (2018) and funded by ZonMw
(grant number 549007001)), the COMBACTE MAGNET EPI-Net project (funded by the Innovative Medicines Initiative Joint Undertaking under grant agreement n 115523 |
115620 | 115737 | 777362 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA
companies in kind contribution) and Charite University Hospital.
* Corresponding author: Maaike S. M. van Mourik, Department of Medical Microbiology and Infection Control, University Medical Center Utrecht, HP G04.614, Hei-
delberglaan 100, 3584 CX Utrecht, the Netherlands.
E-mail address: M.S.M.vanMourik-2@umcutrecht.nl (M.S.M. van Mourik).
https://doi.org/10.1016/j.cmi.2021.02.028
1198-743X/© 2021 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
M.S.M. van Mourik et al. / Clinical Microbiology and Infection 27 (2021) S3eS19S4a r t i c l e i n f o
Article history:
Received 17 November 2020
Received in revised form
24 February 2021










Surveillancea b s t r a c t
Introduction: Healthcare-associated infections (HAI) are among the most common adverse events of
medical care. Surveillance of HAI is a key component of successful infection prevention programmes.
Conventional surveillance e manual chart review e is resource intensive and limited by concerns
regarding interrater reliability. This has led to the development and use of automated surveillance (AS).
Many AS systems are the product of in-house development efforts and heterogeneous in their design and
methods. With this roadmap, the PRAISE network aims to provide guidance on how to move AS from the
research setting to large-scale implementation, and how to ensure the delivery of surveillance data that
are uniform and useful for improvement of quality of care.
Methods: The PRAISE network brings together 30 experts from ten European countries. This roadmap is
based on the outcome of two workshops, teleconference meetings and review by an independent panel
of international experts.
Results: This roadmap focuses on the surveillance of HAI within networks of healthcare facilities for the
purpose of comparison, prevention and quality improvement initiatives. The roadmap does the
following: discusses the selection of surveillance targets, different organizational and methodologic
approaches and their advantages, disadvantages and risks; defines key performance requirements of AS
systems and suggestions for their design; provides guidance on successful implementation and main-
tenance; and discusses areas of future research and training requirements for the infection prevention
and related disciplines. The roadmap is supported by accompanying documents regarding the gover-
nance and information technology aspects of implementing AS.
Conclusions: Large-scale implementation of AS requires guidance and coordination within and across
surveillance networks. Transitions to large-scale AS entail redevelopment of surveillance methods and
their interpretation, intensive dialogue with stakeholders and the investment of considerable resources.
This roadmap can be used to guide future steps towards implementation, including designing solutions
for AS and practical guidance checklists. Maaike S.M. van Mourik, Clin Microbiol Infect 2021;27:S3
© 2021 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Healthcare-associated infections (HAI) represent a significant
disease burden in Europe and are among themost common adverse
events in healthcare settings. HAI are estimated to affect 6.5% of
patients in acute care hospitals on any given day [1,2]. Surveillance
of HAI is a key component of successful infection prevention pro-
grammes. It provides caregivers and policy makers the necessary
information to identify areas of improvement and to guide in-
terventions. The World Health Organization considers HAI sur-
veillance systems to be an essential component of both national
and facility infection prevention and control (IPC) programmes, and
it is included as one of eight core components for effective HAI
prevention and control [3]. Many European countries have estab-
lished regional or national surveillance networks for various
infection types and various patient populations, such as those
receiving care in intensive care units [4,5]. In such networks, a
coordinating centre provides standardized surveillance methodol-
ogy e often in line with (inter)national methods e which supports
data collection, performs analysis of the reported HAI rates and,
depending on the country, shares data for public reporting.
Importantly, surveillance provides information for action, and
feedback regarding surveillance data should stimulate further ac-
tivities to decrease HAI rates. Many local, regional and/or national
level surveillance networks have demonstrated that participation
and consequential increased awareness and/or targeted in-
terventions can truly contribute to a reduction of HAI rates [6e9].
Conventional surveillance of HAI is done by manual chart re-
view and ascertainment; this is time consuming and resource
intensive [10,11]. Under the circumstances of relatively low HAI
incidence in many patient groups (2e5%), the effort in performing
chart review for many patients to identify only a relatively small
number of patients with HAI is inefficient. In addition, conventional
HAI surveillance has low interrater reliability in certain settings,and it depends on the experience and level of training of the pro-
fessionals conducting the surveillance [12e15].
These shortcomings of conventional HAI surveillance have led
to the development and use of automated surveillance (AS) sys-
tems for the identification of surgical site infections (SSI), central
lineeassociated bloodstream infection (CLABSI) or other HAI and
includes both semiautomated and fully automated surveillance
systems (Box 1). A 1986 pioneering report described a computer
system capable of using microbiology results to identify patients
with possible HAI [16]. In 2004, Trick et al. [17] first described
successful automation of CLABSI surveillance. These and other AS
systems rely on routine care data stored in electronic health re-
cords (EHRs) to identify patients who may have developed an
infection and aim to improve efficiency and standardization of
surveillance [18e20]. Although AS has the potential to facilitate
data collection and has been developed and applied in the
research setting within hospitals [21], there are only a few ex-
amples where it has been implemented for large-scale surveil-
lance [22,23]. Because many of the currently available AS systems
were developed in individual institutions with specific local
conditions, they are heterogeneous in their design, aims and
methods as well as in the definitions used. This solitary (stand-
alone) development of AS systems leads to heterogeneity and
poor interoperability between systems and necessitates consid-
erable investment [24].
In order to improve efficiency of surveillance and deliver large-
scale surveillance data, many hospitals, public health institutes and
surveillance networks are currently investing in digital infrastruc-
ture and automation; however, guidance is lacking on how to best
automate the surveillance process and ensure the delivery of sur-
veillance data that are uniform and useful for improving the quality
of care. The transition to AS entails more than converting a manual
process to an automated process; it will affect surveillance targets,





Any form of surveillance where (parts of) the
manual assessment are replaced by an
automated process. This includes fully
automated and semiautomated detection of
healthcare-associated infection (HAI) and
collection, validation and analysis of
denominator data. AS is based on routine care
data, usually by applying appropriate
algorithms.
Routine care data All data documented in an electronic format
during the routine process of care (e.g. surgical
procedures, prescriptions, diagnostic testing
results). These data may be stored and accessed
in various IT systems.
Source data (Raw) data elements from routine care data used
by algorithms to detect (possible) HAI, calculate
the denominator or risk factors (e.g.
microbiology results, admission and discharge
dates, central line days, procedure codes).
HAI surveillance
result
Individual-level HAI status data (HAI yes or no,
including details of HAI) and denominator data
(e.g. central line days, surgical procedures).
Observed HAI rate Aggregate crude rate of HAI calculated based on




AS designed and coordinated by a coordinating
centre and implemented locally under the




AS designed, coordinated and implemented by
the coordinating centre (Table 2).
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on how to move AS from the research setting to large-scale imple-
mentation. Importantly, the aim is not to develop or validate a sur-
veillance system as such or to develop detailed how-to checklists,
but rather to offer high-level conceptual guidance for the future
development of surveillance systems. Surveillance networks and
hospitals can translate this roadmap to their local situation to sup-
port design and implementation of AS. The roadmap does not list all
the characteristics of specific surveillance programmes but rather
focuses on aspects requiring special attention in the transition to AS.
This roadmap discusses the selection of surveillance targets,
different organizational and methodologic approaches to large-
scale automation of surveillance and their advantages, disadvan-
tages and risks; defines key performance requirements of AS sys-
tems and suggestions for their design; and provides guidance on
how to achieve successful implementation. This document is
complemented by other articles in this supplement focusing spe-
cifically on information technology (IT) and governance [25,26].
Methods
This roadmap was written by the PRAISE network (Providing a
Roadmap for Automated Infection Surveillance in Europe), which is
funded by the Joint Programming Initiative Antimicrobial Resistance
(JPIAMR) Network Call on Surveillance (2018). This network brings
together 30 experts from ten European countriesworking in the field
of HAI surveillance (mainly northern, western and southern Europe),
with themajority working in university hospitals and some in public
health institutes. The network included representatives of the
COMBACTE-Magnet EPI-Net network, which provides barrier-free,
timely access to data on the emergence and spread of antimicro-
bial resistance in humans and animals (https://epi-net.eu/).This roadmap is the product of two workshops, teleconference
meetings and review by an independent expert panel with repre-
sentatives from the European Centre for Disease Prevention and
Control (ECDC), the infection prevention and control community,
Eastern Europe and the United States (see the Acknowledgements).
The recommendations andkeypoints formulated in this roadmapare
basedonexpert consensusand iterative reviewof thedocuments, and
no formal assessment or methodology was used. They are meant to
emphasize important aspects of AS implementation and facilitate
implementation initiatives.
The project was divided into work packages that were assigned
to subgroups. Each network member contributed in one or more
subgroups, and a core group with representatives from each sub-
group coordinated the work and monitored project progress. In the
start-up workshop in March 2019, network members reviewed
existing systems for automated HAI surveillance and evaluated
their advantages and challenges; the outcome of this will be re-
ported separately. In addition, essential features of (future) AS
systems were discussed through several flip-over exercises. In the
second workshop (February 2020), the draft roadmap and related
documents were discussed and revised thereafter, also incorpo-
rating comments from the independent expert panel.
Scope and definitions
This roadmap focuses on surveillance of HAI at the regional or
national levels e that is, surveillance performed by groups of
healthcare facilities in a geographical region or country for the
purpose of comparison, prevention and quality improvement ini-
tiatives. Coordinating centres of such surveillance networks can
include surveillance centres, public health institutes or other
parties appointed by participating healthcare facilities. This road-
map does not target prospective prediction of HAI risk, real-time
surveillance, detection of carriage of multidrug-resistant organ-
isms or outbreaks thereof. Because the implementation of an AS
system for HAI requires considerable IT and human resources, this
roadmap is likely to be applied in high-income countries first.
However, as low- and middle-income countries further develop
EHRs and deploy surveillance methods, this roadmap may also be a
landmark for those countries and can be helpful to streamline
development efforts, for example by directly incorporating ele-
ments required for AS when developing EHRs. The roadmap will
use SSI and bloodstream infections (BSI) as examples throughout
because these are commonly surveyed HAI and address the
different challenges encountered when transferring to AS. Box 1
presents key definitions and terminology.
Targets of and approaches to AS
Box 2 provides key points regarding targets and approaches to
AS.
Targets and outputs of AS
In theory, all types of HAI and specific patient populations could
be targeted by AS. Each surveillance network ought to adopt and
develop surveillance applicable to their setting and choose what
types of HAI and what patient populations are the best candidates
for AS and whether AS will completely replace manual surveillance
or just be used for a selection of targets. The following criteria can
help select target HAI for surveillance:
 severe (potentially life-threatening for the patient or associated
with considerable burden and/or cost)
 common (the infection is observed frequently)
Box 2
Key points regarding targets and approaches to automated sur-
veillance (AS)
 Use the most appropriate AS targets in terms of type
of healthcare-associated infection (HAI) and/or patient
population for your purposes and/or needs.
 Choose between semi- or fully automated surveillance
on the basis of the intended use of the surveillance
data, the target of AS, the case definition, stakeholder
preferences and feasibility.
 Choose between centrally or locally implemented
AS. Also consider existing legal regulations for
surveillance or national e-health policies (if any),
stakeholder preferences and feasibility in the setting
where surveillance will be implemented.
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definitions)
 preventable (interventions can prevent the infection).
For AS, the following additional criteria need to be taken into
account:
 accessibility (the source data required for surveillance is acces-
sible in the participating healthcare facilities (See data sources
for AS below))
 standardization (the more standardized the diagnostic and
treatment practices, the more suitable the infection is for
automation).
SSI and BSI are used as examples throughout this roadmap.
Several groups have investigated various approaches to AS to detect
SSI, with some choosing to focus on deep SSI only, given their higher
severity for the patient and increased cost [27e30]. CLABSI have a
high burden of disease [2], but they are relatively rare events, and
their occurrence is largely limited to intensive care units and other
specialized wards (e.g. oncology, nephrology) where central line use
is common. Hospital-onset bacteraemia (HOB) is a quality outcome
measure currently under study in the United States that will also be
included as an example in this roadmap; although HOB represents
all bacteraemias, not just infection, HOB rates may have a higher
power to discriminate between performance in intensive care units
and also include other events that are perceived as preventable, such
as secondary BSI and primary BSI not related to a central line [31,32].
There is a complex relationship between targets chosen for HAI
surveillance, case definitions applied and the feasibility of AS. This isTable 1
Comparison of conventional, semiautomated and fully automated surveillance
Characteristic Conventional Semiau
Designation of HAI state Manual chart review and data extraction Partial
high-pr
Risk of subjectivity or interrater
variability
High Medium




Surveillance workload of IPC
staff
High Reduce
IT/data management workload Low Increas
Abbreviations: HAI, healthcare-associated infection; IPC, infection prevention and controelaborated on further in the paragraphs on semi- or fully automated
surveillance, risks of AS, definitions and data source.
The output of surveillance is the HAI surveillance result: patient-
level HAI status and the denominator. With this, the observed HAI
incidence can be calculated. In SSI surveillance, this is usually the
number of SSI per 100 operated patients (or per 100 surgical pro-
cedures), whereas the output of CLABSI surveillance is most
commonly the number of CLABSI per 1000 central lineedays. HOB
is expressed as the number of HOB per 1000 patient-days.Semi- or fully automated surveillance
Surveillance of HAI can be automated to various degrees
(Table 1), and AS in this roadmap refers to both semi- and fully
automated surveillance.
In fully automated surveillance systems, all steps of surveillance
e from data collection to the determination of HAI status e are
performed without any human intervention or interpretation. A
typical target for fully automated surveillance could be HOB or
Clostridioides difficile infection. For other HAI, e.g. SSI, definitions
need to be adapted to make fully automated HAI ascertainment
feasible. As a result of these adaptations, the construct targeted by
AS may subsequently change [33].
In semiautomated surveillance, the determination of HAI status is
a combination of automation and chart review, for example by al-
gorithms that retrospectively classify cases into categories of HAI
probability. Low-probability patients are considered to be free from
HAI, and high-probability patients undergo manual chart review to
determine HAI status. Using conventional (manual) surveillance
methods and accepted case definitions, patients are then classified
manually as having developed or not developed a HAI [24,34]. Even
though human interpretation is still required in semiautomated
systems, the number of charts that requiremanual review is typically
reduced by >65%, and for some types of SSI >95% [18,35]. Semi-
automated surveillance is being used for SSI and CLABSI [29,36,37].
Both semi- and fully automated surveillance are used in current
AS systems, and both are likely to increase the degree of stan-
dardization of surveillance. All patients are systematically evalu-
ated, and the effort dependency of surveillance is reduced or absent
[27,35,38e40]. The manual confirmation step in semiautomated
surveillance still allows a certain degree of interrater variability, but
simultaneously it also allows for nuanced clinical interpretation of
the patient's condition [24,41,42]. Because there is no manual re-
view step to confirm infections, fully automated surveillance re-
quires that source data be highly standardized, with respect to
interpretation and completeness as well [24].
Deciding whether fully or semiautomated surveillance should
be implemented depends on many factors, such as data availability,
level of IT and data management support, the target of surveillance,
case definitions of HAI used and stakeholder and user preferences.
The choice of surveillance method should be guided by thetomated Fully automated
automation; manual chart review for
obability patients only





l; IT, information technology.
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surveillance may promote clinicians' and IPC staff's acceptance of
the surveillance result, whereas fully automated systems allow a
standardized assessment of large numbers of patients and may be
more suitable when data are generated for public reporting or
assessment of pay-for-performance.
Centrally or locally implemented AS
This roadmapwill explore twoorganizational approaches to large-
scale AS: centrally implemented AS and locally implemented AS.Fig. 1. Schematic representation of centrally and locally implemented AS. This roadmap f
surveillance efforts. Possibilities in different countries will vary depending on legislation w
records. Abbreviations: HAI, healthcare-associated infection; IPC, infection prevention and
Table 2
Description of centrally and locally implemented automated surveillance as used in this
Characteristic Locally implemented AS
Standardized definitions of HAI Yes
Semi- or fully automated surveillance Semiautomated or fully automated
Responsibility for the development of IT
systems and algorithms
Participating healthcare facility, bas
coordinating centre.
Source data collection and the application of
algorithms
Participating healthcare facility; ma
third party.
Validation of source data collection Participating healthcare facility; sup
coordinating centre.
Collection of HAI surveillance data, calculation
of HAI rates and analysis of trends
Coordinating centre; participating h
may perform additional in-depth
Feedback to participating healthcare facilities Coordinating centre provides netwo
along with facility-level feedback.
Abbreviations: AS, automated surveillance; HAI, healthcare-associated infection; IT, infoThese terms refer to the level where the responsibility for the imple-
mentation of (automated) surveillance is positioned (Fig. 1, Table 2).
Within each approach, there is room for multiple solutions, and
some variations will be illustrated where relevant. In the design
phase, the choice between centrally and locally implemented AS
must be made, as this will guide future implementation efforts. In
this decision, inherent differences between the two approaches and
their associated risks and advantages need to be weighted along,
with legal regulations or national e-health policies (if any), stake-
holder preferences and an assessment of feasibility in the specific
setting where AS will be implemented.ocuses on surveillance within networks where a coordinating centre coordinates the
ith regard to data protection and privacy, as well as the level of digitization of health




surveillance. Most likely fully automated surveillance.
ed on guidance from Coordinating centre, with local support; completely
standardized across participating healthcare facilities.
y be outsourced to a Coordinating centre; their programmes may be
implemented locally.




Coordinating centre; participating healthcare facilities
may also analyse their own HAI trends.
rk-level feedback Coordinating centre provides network-level feedback
along with facility-level feedback.
rmation technology.
Box 3
Key points regarding the design of automated surveillance
 Identify and involve relevant stakeholders in the
design phase.
 Formulate required features of automated
surveillance (AS).
 AS, in particular when fully automated,
requires reconsideration of healthcare-associated
infection (HAI) case definitions to address limitations
in data availability and methodologic aspects of case
ascertainment.
 Formulation of new HAI case definitions must take
into account standardization, source data availability,
length of follow-up, acceptance by infection prevention
and control (IPC) staff, clinicians and hospital
managers, endorsement by stakeholders, vulnerability
to practice variations and comparability.
 The source data required to participate in AS should
ideally be kept to a minimum; it is recommended to
specify a minimum data set for participation.
Performing an inventory of data availability and
quality in participating healthcare facilities before
designing the system is strongly recommended.
 The use of administrative data such as diagnosis
and procedure codes as a sole source of data is
insufficient to reliably perform HAI surveillance.
 Key criteria to select algorithms for AS include
sensitivity, specificity, feasibility (with respect to data
collection and methodology), clinical and IPC staff
acceptance and robustness to changes in clinical
practice.
 Generally, algorithms combining multiple data
sources for case finding have higher sensitivity
than those
relying on a single indicator.
 Algorithms must be validated against the best
available reference standard.
 Feedback of HAI surveillance results from the
coordinating centre to participating healthcare facilities
should be timely and include a flexible reporting tool
that allows participating healthcare facilities to generate
reports that fit their needs.
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within a surveillance network of participating healthcare facilities,
and the responsibility of overall AS design and coordination lies
with the coordinating centre. The centre plays a pivotal role in the
design of the surveillance methodology, including the provision of
stringent and detailed standardized case definitions and data
specifications, preferably in accordance with other (inter)national
protocols. Centrally implemented surveillance likely requires a
more rigid governance of the partners involved, as more advanced
consensus on essential elements of the surveillance methodology is
needed. Centrally implemented surveillance may make AS more
accessible to participating healthcare facilities that do not have the
resources available to implement AS locally, and it may be easier for
centrally implemented AS to obtain the required funding.
Conversely, locally implemented surveillance may offer some
flexibility to participating healthcare facilities to adapt the sur-
veillance to their local needs and resources, as long as the output
meets the requirements of the coordinating centre and the quality
of the surveillance is appropriately validated. This possibility for
adaptation to the local situation may increase the relevance of the
surveillance results for end-users (including clinicians) and
possibly hospital management. It must be noted that when the
surveillance network facilitates manual surveillance next to semi-
automated surveillance (e.g. during the implementation phase),
semiautomated surveillance is likely to have better sensitivity than
manual surveillance, and comparability between both methods
may be affected.
Risks of AS
As alluded to previously, the transition to AS is likely to increase
surveillance capacity and reliability, but the change in methodology
has several consequences that need to be explicitly considered
before designing and implementing AS. These need to be commu-
nicated with stakeholders. Firstly, there is a complex relationship
between the surveillance target and the definitions used. Adapting
definitions will inevitably lead to changes in the target (or construct)
under surveillance, and therefore interpretation of data will not be
similar. This break in the data needs to be considered when
comparing results to historical data and interpreting prevention
studies. In addition, the development of new methods and defini-
tions poses the risk of losing comparability among surveillance
networks as they choose different approaches and methodologies
for AS. This risk may be mitigated by collaboration among surveil-
lance networks and (inter)national surveillance entities, such as the
ECDC. It is also imaginable that, especially in the start-up phases, AS
will run next to conventional surveillance, and these methods will
produce results that cannot be compared. In addition, when AS is
rolled out, research is needed to determine whether the results
obtained by AS can be the driver of quality improvement [20,24].
Secondly, as with conventional HAI surveillance, the validity and
reliability of surveillance will need to be carefully assessed and
monitored, as automation in itself is not a guarantee of quality, and
seemingly small differences in methodology can have important
consequences on the results [20,43]. This applies to both the
initiation phase and later phases. Measures to ensure the quality of
AS will be discussed throughout the next sections of the roadmap.
Finally, ongoing research is needed to optimize AS methods, to
assess whether AS can contribute to reduction of HAI and to
determine the best approach to implementation (see Areas of
future research).
Design of AS
Box 3 lists key points regarding the design of AS.Requirements for AS
Success in designing and implementing AS largely depends on
identifying and engaging internal and external stakeholders.
Balancing their needs and adapting the design of the system
accordingly to obtain their commitment is key.
Table 3 delineates crucial features required of AS for it to be of
value to users and other stakeholders e and ultimately to result in
driving quality improvement.Definitions
Surveillance definitions of HAI are often different to those used
in clinical practice, especially when managing individual patients
with infections or deciding when to initiate therapy with anti-
infective agents. Epidemiologic case definitions for HAI prioritize
consistency and comparability. Hence, surveillance definitions
Table 3
Features required from automated surveillance
Feature Details
Stakeholder support and endorsement by clinicians Leadership and acceptance by IPC personnel.
Surveillance of relevant events with sufficient clinician acceptance.
Endorsement at all levels, both internal and external (Box 5).
Secured resources Human and financial resources for design and production phase.
Long-term commitment to guarantee continuous operation.
Sufficient number of participating healthcare facilities Participation feasible for most healthcare facilities.
Useful reference data generated.
Adequate validity and standardization of methods Comparable HAI surveillance results (HAI status data and denominator).
Central validation and aggregation of HAI surveillance results.
Continuous maintenance and validation.
Flexibility in participation Possibility for modular participation of healthcare facilities.
Data collection Required data collection kept to a minimum, with specification of a minimum data set.
Integration with national eHealth strategy (if relevant) and adherence to relevant IT standards in healthcare.
Governance and trustworthiness Adequate validation and transparency of methods.
Appropriate governance structure.
User friendliness Interface simple to use for end users.
No additional manual data entry by clinicians.
Feedback of results and reporting to clinicians Timely and flexible generation of reports (local and central).
Centrally collected data accessible for participating healthcare facilities.
Correction for case mix, hospital type, device use, comorbidities and other factors whenever possible.
Reporting to the public Standardized or stratified data reported when available.
Graphical representation of results used whenever possible.
Incorporates HAI data reporting requirements established by regional or national regulatory bodies or
coordinating centres, as applicable.
Training Necessary for interpreting and presenting surveillance results.
Abbreviations: HAI, healthcare-associated infection; IPC, infection prevention and control; IT, information technology.
Hospital-onset bacteraemia (HOB): Any positive blood cul-
ture obtained >48 hours after admission until discharge,
including repeat cultures and contaminants.
M.S.M. van Mourik et al. / Clinical Microbiology and Infection 27 (2021) S3eS19 S9historically have been developed to be as clear and as objective as
possible; when used in different healthcare facilities or by different
surveillance personnel, differences in surveillance results should be
genuine and not the result of different interpretations. As a
consequence, they do not include all potentially relevant clinical
information [44].
When transitioning to AS, several challenges are encountered
with respect to case definitions of HAI. In some cases, the source
data required to apply conventional case definitions cannot be
extracted in a suitable format from EHRs (in particular clinical signs
and symptoms or the clinical diagnosis of HAI), or the transition to
fully AS entails simplifying definitions to allow for ascertainment
by algorithms (e.g. methodologic aspects). The aspects that need to
be taken into account when selecting definitions for AS are listed in
Box 4.Box 4
Aspects that need to be taken into account when selecting defi-
nitions for automated surveillance
 Endorsement of healthcare-associated infection
rates by clinicians and other stakeholders.
 Sufficiently clear criteria with minor subjectivity.
 Availability of source data.
 Length of follow-up and need for postdischarge
surveillance.
 Vulnerability to variation in clinical practice (e.g.
sampling frequency, treatment regimens) and
documentation.
 Comparability across surveillance networks or
over time.
 Purpose of surveillance activity (e.g. quality
improvement, public reporting).Example 1 describes two surveillance definitions for bacter-
aemia and bloodstream infections that are amenable to fully AS.
HOB is a concept currently under study in the United States
[31,32,45]. The Danish Healthcare-Associated Infections Database
(HAIBA) bacteraemia definition is included in the Danish AS
network [39].
Example 1. Definitions and required data elements for fully
automated surveillance for bacteraemia and bloodstream
infections Blood culture results, including date of sampling.
 Specific time interval with respect to admission and
discharge.
Denominator: patient-days.
Danish Healthcare-Associated Infections Database (HAIBA)
hospital-acquired bacteraemia: A positive blood culture
with growth of a microorganism that is considered to be
pathogenic. The sample time must fall within a period from
48 hours after the start of hospital contact to 48 hours after
the end of contact. A new bacteraemia is counted if a new
positive blood culture is found >30 days after the previous
positive blood culture.
 Blood culture results, including date and time of sampling
(also outside hospital admissions).
 Specific time interval for start and end of hospital contacts
(admissions and outpatient visits).
Denominator: patient-days at risk.
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retain conventional case definitions; the manual confirmation step
allows for integration of information not available in a suitable
format in EHRs and for nuanced clinical interpretation. In addition,
possible HAI can be identified using proxy indicators (e.g. admis-
sion data, antimicrobial use, reoperations). Fully automated sur-
veillance more often requires adaptation of definitions, although
it may be envisioned that some adaptation to EHRs or more
complicated algorithms relying on text mining and/or machine
learning may address some of these challenges in the future.
Depending on the approach chosen for AS, definitions may need
to be modified, and clinical information relevant for clinician's buy-
in may be lost when applying AS. However, this clinical information
is often subjective and not collected in a uniform matter, so this
disadvantage should be balanced against the benefits of AS. When
adapting HAI definitions, the aim of surveillance is crucial. In the
case of using surveillance data for internal quality improvement,
the endorsement of the definitions by the clinicians and IPC staff is
paramount. If mandatory HAI surveillance e and (mandatory)
public reporting in particular e is in place, standardization of data
and comparability will be essential. Importantly, modifying the
surveillance definitions often entails changing the target of sur-
veillance (see ‘Targets and outputs of AS’) and the characteristics of
the HAI detected; in addition, changes to definitions will preclude
comparison with historical data or previous benchmarks. Finally,
the effects of differences in sampling frequency (e.g. frequency of
taking blood cultures) must be assessed and adjusted for because
this has a major impact on rates of HAI identified.Data sources for AS
AS, both centrally and locally implemented, requires extraction
of the necessary source data from EHRs (see the accompanying IT
article [25]). For the sake of feasibility, the data required to
participate in AS should ideally be kept to a minimum, and it is
recommended to specify a so-called minimum data set (MDS) for
participation. This MDS defines the required source data in an
accessible form for application of algorithms and determining HAI
status, calculation of the denominator and meaningful interpreta-
tion of results (e.g. patient characteristics for case mix correction).
Participating healthcare facilities can subsequently assess their
eligibility for participation, prioritize their IT resources on the basis
of this MDS or incorporate MDS requirements in negotiations with
EHR vendors.Table 4





Admission/discharge dates, at unit and hospital level MDS
Device use d
HAI state data





Patient self-reporting (ambulatory/digital app) Optional
Abbreviations: BSI, bloodstream infection; CLABSI, central lineeassociated bloodstream i
site infection.
a Where data can be found/extracted can vary by hospital. Data locations are as follow
pharmacy systems.
b Data are generally reliable, but formatting may differ.The exact specification of the MDS must be defined by the
coordinating centre and will depend on the targeted HAI, case
definitions, algorithms used and the IT resources of participating
healthcare facilities. Performing an inventory of the source data
availability and its quality in participating healthcare facilities
before designing the system and defining the MDS is strongly
recommended. Most existing AS systems rely on clinical data
sources, such as admission and discharge records, culture results
and antibiotic prescriptions (Table 4). In some instances, procedure
and diagnosis codes assigned for the purpose of billing or epide-
miology have been used for HAI surveillance, either as a comple-
ment to clinical data or as a stand-alone method. The use of such
administrative data as a sole method to identify HAI e although
generally easily accessible e is insufficient to reliably perform HAI
surveillance [46].
Data may be stored in EHRs in a structured (e.g. admission dates,
procedures, microbiology cultures) or unstructured format (e.g.
narrative description of clinical signs and symptoms); the latter are
more cumbersome to work with. If data are systematically docu-
mented in EHRs in a structured way and their reliability is peri-
odically validated, the quality of the data extracted is likely to
surpass the quality of manually extracted data because recording
errors are eliminated [47].
Importantly, the HAI case definition chosen will ultimately
dictate the requirements for theMDS. Simplified definitions relying
solely on data commonly available in a structured format may
facilitate fully automated surveillance. The required source data
must then be available in all participating healthcare facilities and
documented in a similar fashion. Collection of data on clinical signs
and symptoms or judgement regarding the source of infection may
not be feasible when relying on structured EHRs data [33]. Some AS
systems use natural language processing or text mining to trans-
form free text into structured information [48e50]. However,
developing natural language processing algorithms requires
considerable investments e possibly local for each hospital e and
relies on adequate clinical documentation. The added value of
incorporating this technology in addition to the use of structured
data has not yet been firmly established [51e54].
With respect to postdischarge surveillance, if patients seek care
at the hospital where the initial surgery was performed, SSI will
likely be picked up if data collection is extended to include this time
period and includes outpatient care. This postdischarge surveil-
lance may be complemented by (electronic) patient self-reporting,
for example using smartphone applications [55] or e if dataLocation of dataa Quality of data
BSI
d A Generally good
MDS A Generally good
MDS (CLABSI) C Not well determined
MDS L Generally goodb
Optional C/P Generally goodb
d A/C Generally good
d A/C Not well determined
d A/C Generally good
Optional C Generally good
nfection; HAI, healthcare-associated infection; MDS, minimum data set; SSI, surgical
s: A, administrative database; C, clinical notes; L, laboratory information systems; P,
Table 5
Features to consider when selecting an automated surveillance (AS) algorithm
Characteristic Locally implemented AS Centrally implemented AS
Feasibility of source data collection Ideally feasible in all hospitals where it will be
used.
Participating healthcare facilities can adapt data
collection to their setting, albeit with
adequate validation and to a degree agreed
with the coordinating centre.
Must be feasible in all hospitals where it
will be used.
Complexity, methodology, maintenance and
technical feasibility
Implemented in participating healthcare
facilities. Methodological feasibility is
paramount.
Implemented at coordinating centre or
provided in script to hospital.
More room for complex models.
Clinical interpretability and acceptance Method should be understood and accepted by
end users and stakeholders.
If semiautomated, manual confirmation may
improve clinical acceptance.
Method should be understood and accepted
by end users and stakeholders.
Black box systemsmay limit interpretability
and acceptance.
Robustness to differences or changes in clinical
practices (e.g. diagnostic frequency)
Interpretability and comparison over time or
across hospitals.
If semiautomated, sensitivity should be
maintained; small losses in specificity
can be corrected by manual confirmation.
Interpretability and comparison over time
or across hospitals.
Performance characteristics Meets prespecified criteria for sensitivity and
specificity.




Especially in setting of public reporting or pay
for performance.
Especially in setting of public reporting or
pay for performance.
Classification algorithm
Patients are included in the surveillance on the basis of
procedure codes.
All patients who meet three of the following criteria within
120 days after surgery should undergo manual chart re-
view; all others are considered free of surgical site infection.
 Microbiologic culture from relevant body site (e.g. tissue,
blood): positive culture, regardless of species, or five or
more cultures taken from relevant body site.
 Reoperation by initial specialty (e.g. orthopaedics).
 Fourteen days or more (cumulative) of antimicrobial
prescribed, including outpatient.
 Initial length of stay >14 days or readmission to initial
specialty.
Determinants of success
 Check agreement of algorithm against actual clinical
practice in participating healthcare facility.
 Avoid overly specific criteria in order to increase robust-
ness to changes in clinical or coding practices (e.g. reli-
ance on specific antibiotics or specific procedure codes).
 Combine multiple criteria for case finding to improve
sensitivity.
 Perform yearly maintenance of the selection of procedure
codes to include in the surveillance.
 Develop a method to account for multiple procedures
during one surgery and to perform validation of the pro-
cedure inclusion process.
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data (such as readmissions) across healthcare providers. In cen-
trally implemented surveillance, records could be matched on a
higher level to allow for data collection from other sources,
including data from ambulatory and primary care, other hospitals,
billing records or other databases [56].
What data on case mix or risk factors should be considered
mandatory for participation depends on striking a careful bal-
ance between collecting the required information and main-
taining feasibility. The importance of risk adjustment will also
depend on the intended use of surveillance data. In particular,
in a setting of public reporting or pay-for-performance ana-
lyses, collection of reliable data on risk factors will be
paramount.
Algorithm selection and design aspects
Because the exact details of algorithm development are
constantly evolving, this roadmap will not provide detailed tech-
nical guidance on how to design algorithms but instead highlights
characteristics to consider when selecting or designing an algo-
rithm (Table 5). The accompanying IT article addresses some
technical aspects of algorithm implementation ([25] See ‘Surveil-
lance algorithms’).
Generally, algorithms combining multiple data sources for case
finding have higher sensitivity than those relying on a single in-
dicator, until a point of saturation is reached [18,57,58]. Impor-
tantly, models relying solely on microbiologic culture results or
mandating a positive microbiology culture may lead to both under-
and overdetection of SSI because positive cultures are not always a
prerequisite for SSI diagnosis, and conversely because a positive
microbiology result does not always reflect the presence of an
infection [59]. Ideally, algorithms are defined such that they align
with clinical practice and do not lose their sensitivity with minor
modification in clinical practices [29]. Especially in the setting of
mandatory reporting or financial consequences, the vulnerability of
the algorithm e or any method of surveillance e to (inadvertent)
manipulation needs to be considered.
Most AS systems, both semi- and fully automated, rely on clas-
sification algorithms to determine HAI state [18,27,39,60e62].Example 2 provides an example of a simple algorithm that can be
considered for semiautomated surveillance [27,29].
Example 2. Semiautomated surveillance algorithm for deep sur-
gical site infection after hip/knee arthroplasty and determinants of
success
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multivariable regression models that apply a weighted regression
formula to estimate the probability of having had an infection
[63,64]. Expanding on classical multivariable regression, fuzzy
logic, machine learning and artificial intelligence techniques are
increasingly applied to detect possible cases of HAI [65e67]. These
more sophisticated techniques generally achieve higher specific-
ities at similar sensitivities; however, the complexity of the meth-
odology may preclude a simple and straightforward understanding
of the classification by clinicians and IPC staff. Future research will
need to demonstrate the performance of artificial intelligence and
machine learning technologies for AS and determine their most
useful utilization. Application of algorithms, both simple and
complex, requires specialized expertise and may increase the need
for data management and statistical support within both coordi-
nating centres and participating healthcare facilities (See
‘Commitment and resources’).
Before accepting algorithms for use, their performance must be
assessed with respect to identifying HAI and quantifying the de-
nominator (See ‘Validation of AS’). The performance of AS systems
is often related to surveillance by conventional methods. Hence,
any assessment of system performance will also depend on the
quality of this reference standard.When evaluating semiautomated
surveillance, the outcomes can be compared to conventional sur-
veillance (i.e. surveillance that is based on manual chart review).
Generally, cases identified as high probability are compared to the
manual reference standard. On the basis of the literature, a sensi-
tivity of 90% is achievable for most HAI and should be considered
the minimal performance level in semiautomated surveillance
[68,69]. The positive predictive value (PPV) of the algorithmmainly
reflects the efficiency of the screening process and will also depend
on the incidence of the targeted HAI; a minimal performance
cannot be given. The acceptable value will depend on the re-
quirements set by users. In fully automated surveillance, there is
usually a trade-off between sensitivity and specificity. Depending
on the targeted application and objective of surveillance, the end
users and stakeholders must choose what outcome measure is
prioritized, sensitivity or specificity and PPV. It can be argued that
confidence in events detected being true cases is better than
identifying all possible cases. These considerations will define
acceptance criteria for AS.
In contrast, when definitions are altered in order to accommo-
date AS, a head-to-head comparison to reference data collected
through conventional surveillance may not be informative enough
because both definitions may target different entities. Besides
comparing algorithm performance to the best available reference
standard, analyses may be complemented with other outcomes to
assess the usefulness of the events detected, such as mortality,
length of stay or an association with cost.
Feedback and reporting of outcomes
In order to drive quality improvement cycles, timely feedback of
surveillance results from the coordinating centre to the participating
healthcare facilities is paramount [3]. Depending on the country's
policies and legal regulations on HAI surveillance, this may be
feedback of aggregated results only, confidential feedback to the
participating healthcare facilities with a comparison of the hospitals'
HAI rates to aggregated rates from comparable hospitals, or results
may be made available to the general public or payers [70].
Feedback of HAI surveillance results from the coordinating
centre to participating healthcare facilities may be facilitated byusing a digital environment with a flexible reporting tool that al-
lows participating healthcare facilities to generate reports that fit
their needs, both in centrally and locally implemented surveillance
(See ‘User interfaces’ and ‘Secure data transfer’ in [25]). Ideally,
hospitals receive their crude HAI rate and a rate adjusted for
available risk factors, including a visual presentation of data though
an (interactive) dashboard. In the case of centrally implemented AS
e where the HAI surveillance result is determined in the coordi-
nating centre e feedback of the patient-level HAI surveillance
result and line listings should be organized in compliance with
privacy regulations. In addition, AS may lead to a more timely
feedback of rates and comparison to reference data, and reports
may be accompanied clear steps to be taken using the data (goal
setting, action planning), thus promoting the use of data in quality
improvement programmes. Next to providing feedback, the coor-
dinating centre is in a position to analyse the HAI surveillance re-
sults in order to detect trends and outbreaks and to notify
participating healthcare facilities. Given the large amounts of data
that may be collected, this will require the development of dedi-
cated methods. This carries a responsibility that should be
addressed in the design phase and requires adequate resources and
governance.
Providing a secure environment for feedback and differentiating
the reporting for different audiences (hospitals, payers, public) can
be helpful to provide all stakeholders with the information relevant
to them.Implementation of AS
Box 6 lists key points to achieve successful AS implementation.Commitment and resources
An array of published articles point to the fact that although AS
systems exist and have been validated in the academic literature,
their adoption is still limited [71]. Data suggest that in hospitals
with strong leadership, organizational support and engagement
with patient safety, those involved in surveillance feel more sup-
ported in implementing such systems and overcoming barriers,
leading to greater satisfactionwith AS [71]. Successful organization,
implementation and maintenance of AS first and foremost requires
a clear definition of the purpose of surveillance and commitment
from relevant stakeholders (Box 5), both at the level of the coor-
dinating centre and the participating healthcare facility. This in-
cludes establishing the political and scientific background through
alignment with national e-health strategies, consultation with
professional organizations and relevant national societies as well as
creating support locally among hospital management, clinicians,
infection control and IT staff. In addition, cultivating an institutional
culture that embraces technology and views change positively is
also likely to improve data quality [72]. Clear communication of the
potential benefits for clinicians and patient outcomes may help
create support and the involvement of clinicians in all steps of
implementation may further increase the quality and impact of
surveillance. Governance aspects of stakeholder involvement
appear in the governance document ([26] See “Engaging with
participating healthcare facilities”). Additionally, adoption of AS
should also include training of staff regarding the methodology and
the interpretation of data for useful feedback and quality
improvement. This training should also be incorporated in profes-
sional training programmes (Appendix A) [71].
Box 6
Key points to achieve successful automated surveillance
implementation
 Successful organization, implementation and
maintenance of automated surveillance (AS) requires
commitment from relevant stakeholders.
 The purpose of surveillance should be clearly defined.
 An implementation strategy should include the training
of participants regarding methodology and
interpretation of data (Appendix A).
 Long-term funding must be secured to cover costs of
AS development and operation, both at the level of the
coordinating and participating healthcare facilities.
 Implementation and operation of AS will require
different skills than conventional surveillance, and
training should be included in professional training
programmes.
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considerable investment of resources. Coordinating centres should
secure long-term funding for establishing and maintaining the
system. Adoption of AS also requires substantial investment from
participating healthcare facilities to implement AS within their IPC
departments and to modify and maintain IT systems and for
training of personnel. These needs should be addressed at the
outset of implementation projects. Implementation of AS will
likely result in a reduction of human resources needed to perform
surveillance through chart review, but importantly, it will ask for
investment of different skills to implement and operate the sys-
tem. For example, strengthening the availability of epidemiologic,
IT and statistical support in IPC departments will be important.
Resources also need to be secured for maintenance and ongoing
improvements to the systems. Despite these investments, the
transition to AS is expected to free up IPC personnel, and resources
may be refocused on prevention efforts within the organization,
although the achieved benefits have not been formally quantified
to date.Box 5
Potential stakeholders in (automated) HAI surveillance
Participating healthcare facilities:
 Infection prevention and control personnel, including
clinical microbiology, infectious disease or hospital
epidemiologists, and, if applicable, clinical pharmacists.
 Clinicians (doctors, nurses, other healthcare workers).
Hospital management, including patient safety and risk
management.
 Hospital information technology (IT).
 Data protection officer, legal department and ethical
committee.
Coordinating centre:
 Surveillance network management.
 IT and data protection officers (including ethical
committee).
 Public health institutes and other related scientific
institutes.
Community/society:
 Patients, patient groups and, if applicable, the general
public.
Government agencies and other relevant bodies in
healthcare:
 Ministry of health (or equivalent).
 Regional and national public health authorities.
 Insurers and other payers.
 Data protection agency.
 Relevant professional societies.
Potential third parties:
 Independent IT companies and IT service providers.
European and other international partners:
 European Commission.
 European Centre for Disease Prevention and Control
(ECDC).
 World Health Organization (WHO).
 Responsibilities should be assigned to each relevant
party at the start of implementation (Table 6).
 IT development should comply with current technical
and data protection standards with regard to
interoperability, data storage and sharing.
 Allow for sufficient piloting and phased development,
which are crucial for successful implementation.
Modular participation and flexibility are probably
crucial in order to achieve successful large-scale
adoption.
 Develop an adequate governance structure to
encourage transparency and accountability for all
stakeholders.
 For endorsement of the surveillance network by
stakeholders, including the public, transparency
regarding the purpose, data collection, data handling
and validation is essential.
 Involve legal specialists and data protection officers
who understand the purpose of AS from the start of
development to ensure adequate governance of data
access and sharing.
 Implement changes in legal regulations relevant
for healthcare-associated infection surveillance, as
necessary.
 Performance of AS can vary across different
clinical settings and patient populations; it should
undergo clinical and technical validation in all contexts
where it will be used, at initiation and then periodically
after implementation.
 Specifically for semiautomated surveillance,
ensure adequate validation of the manual
ascertainment, as is currently also performed in
conventional HAI surveillance. This remains essential.
 Securing sufficient resources for maintaining and
adapting the system is paramount, including
epidemiologic and IT support in the coordinating
centres and in participating healthcare facilities.
 Throughout implementation, it is recommended
that the coordinating centre and participating
healthcare facilities evaluate whether the surveillance
system provides meaningful data.
Table 6
Tasks and responsibilities that must be covered in AS, including assignment to specific roles






Senior management Secure long-term commitment and funding for AS. ✓ ✓
Enforce adherence to surveillance protocol and data and
privacy regulations.
Clinical leadership Medical director Promote clinician buy-in of surveillance results. ✓ ✓
IT strategy IT manager Ensure appropriate (human) resourcing and infrastructure. ✓ ✓




Data protection officer, chief
information officer
Ensure privacy and public benefit requirements are met for
any personal identifiable information collected.
✓ ✓
Optimize technical and organizational measures for data
protection.
Central coordination Surveillance network
management
Specify definitions, systems, design, quality monitoring
(including validation), communication, training.
✓
Local coordination IPC lead and team Coordinate and specify of local surveillance systems, design
and validation.
✓
Communicate with (local) IT and coordinating centre.
Performmanual review of selected patients' charts if needed.
Consent or accept use of data
(if applicable)
Patients If applicable under current European and national legislation. ✓
Optional: collect data after discharge.
Documentation in EHRs Medical and nursing staff Document routine care data as part of daily workflow. ✓
Management of local IT
infrastructure
Local IT staff and lead, in IPC
and hospital wide
Build and maintain EHRs modifications and facilitate data
extraction.
✓
Perform version management of technical specification.
Data management Data manager Perform data extraction and apply algorithms. ✓ ✓




Analyse trends and provide benchmarking information. ✓ ✓
Detect clusters of HAI.
Generate reports for reporting and local use.




Interpret outputs and close the surveillance loop, driving
improvement.
✓
Provide feedback regarding surveillance targets.
Abbreviations: AS, automated surveillance; EHRs, electronic health records; HAI, healthcare-associated infection; IPC, infection prevention and control; IT, information
technology.
Box 7
Phasing in automated surveillance
Example Aspect suitable for phasing
No. of participating
healthcare facilities
Start with a small number of pilot
hospitals.
HAI targeted by AS Start with surveillance of a few and
technically straightforward HAI; allow
for optional addition of other types of
HAI.
Data sources In semiautomated surveillance, start with
simple algorithms that can be refined
based on data availability.
Algorithm complexity Techniques can be upgraded based on
resources in participating healthcare
facilities.
Risk factor data Start with fewer risk factors, then expand
based on data availability.
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When implementing (automated) surveillance systems, re-
sponsibilities should be assigned to each relevant party. Table 6
details the suggested roles and responsibilities at the level of the
coordinating and participating healthcare facility. Appendix B
contains a more detailed description of all potential stakeholders
and their roles and responsibilities; see also the governance article
[26]. The exact professional profile most suitable for each task can
be defined according to the local situation.
Development and implementation strategies for AS
As mentioned above, AS can be approached from a central or
local perspective, with each approach having specific features, ad-
vantages and limitations (See ‘Centrally or locally implemented
AS’). When moving towards large-scale AS, allowing for sufficient
piloting and phased development is crucial in order to achieve
successful large-scale adoption. Modular participation and flexi-
bility will likely contribute to successful implementation. Impor-
tantly, implementation challenges may vary substantially between
countries as a result of differences in organization of the healthcare
system, history, extent and the methodology of existing HAI sur-
veillance, political interest in this subject, resources available and
existing regulations (e.g. data protection).
The ‘minimum viable product’ concept may be useful in staging
development. This concept focuses on first delivering a product
with just enough features to satisfy early adopters and provide
feedback for future improvement. Developing a product with more
features before initial adoption tends to increase costs and risks e
for example, as a result of incorrect assumption or unforeseenincompatibilities [73]. Conversely, when staging development,
choices are ideally made such that resources are used efficiently,
and expansions or upgrades do not require extensive redevelop-
ment and reinvestment of already existing parts. Further systems
should be designed such that they require the least reprogramming
if other systems such as the EHRs or administrative systems were to
be replaced. In addition, there should remain sufficient incentives
to upgrade systems or expand participation to allow for additional
modules. Implementation of AS may benefit from codevelopment
with other automated systems for quality improvement, for
example surveillance of other, noninfectious or adverse events. The
prevent too slow a pace for implementing important up-
grades and declining commitment as funding ceases.
 Data validation to ensure data acceptance among clinical
end users.
 Build competence at clinic level in using the data feedback
system to retrieve relevant data for local improvement
programmes.
Abbreviations: AS, automated surveillance; EHRs, electronic health records;
HAI, healthcare-associated infection; IPC, infection prevention and control;
IT, information technology.
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as an illustrative example ([25] Fig. 2).
Development of large-scale AS can be phased in various ways,
both in locally and centrally implemented surveillance, thereby
providing flexibility to the participating healthcare facility and/or
the coordinating centre to implement AS, as shown in Box 7.
Aside from these possible phases in development, a range of
approaches to communication infrastructure is available to imple-
ment both centrally and locally implemented AS, and detailed
scenarios can be found in the IT article ([25] ‘communication be-
tween participating hospital and coordinating centre.’). For
instance, centrally implemented AS can either entail applying the
algorithm within the coordinating centre on source data provided
by healthcare facilities, or the coordinating centre can provide a
programming script for the standardized algorithms that health-
care facilities can run locally on source data and subsequently send
the HAI result sets to the coordinating centre. This latter approach
will, however, require careful version management to guarantee
comparability across healthcare facilities. In locally implemented
AS, source data collection and the application of algorithms could
be supported by the coordinating centre providing algorithms and
methods to participating healthcare facilities. Alternatively, ana-
lysesmay be outsourced to a third party (under the responsibility of
the participating healthcare facilities) if there are insufficient local
resources to implement and maintain systems. In all scenarios,
detailed technical specifications are crucial; small differences in
implementation can have serious consequences on the events
detected [43]. The IT requirements for AS should be incorporated in
organizations' commitment to IT, and strategies for IT both na-
tionally and locally and all IT developments should comply with
current technical and data protection standards with regard to
interoperability, data storage and sharing and infrastructure design
([25], ‘Standardization and Interoperability’).
Example 3 describes experiences obtained from the imple-
mentation of the Swedish Infection Tool. This tool collects in-
dications for antibiotic prescriptions to detect all types of HAI and
has been implemented nationally in Sweden.
Example 3. Experiences from early phases of implementation of
the Swedish infection tool1. Committed hospital managers and IPC professionals who
accept responsibility are facilitators to implementing AS.
2. An implementation group of people needs capacity and
competence in the following areas:
 Project leadership.
 Competence in local working processes for diagnosing
and managing infections.
 Competence in the use of EHRs locally.
 Communication and education planning for reaching out.
 Technical implementation needs of the system.
 Documentation of IT infrastructure built to ensure correct
labels of places, persons and data types.
 IPC competence to ensure the data generated are mean-
ingful for HAI prevention.
3. Important early tasks
 Keep an updated list of persons involved and responsible.
 Conduct a risk analysis for the implementation project.
 Develop a long-term plan for implementation, system
development and securing future funding; this canPrivacy, data security and public trust
Data safety and responsible data sharing are pivotal for
(personalized) medical data. Thus, the development and imple-
mentation of large-scale AS will require specific attention to data
privacy, data security and maintaining public trust. The design of
systems should be compliant with international, national and local
regulations, such as the General Data Protection Regulation (GDPR),
national laws and specifications as well as local policies of partici-
pating healthcare facilities. The implications of the GDPR and the
possibilities to analyse personal and/or medical data depend on the
purpose of surveillance. In many situations, the explicit consent
given by the data subject for a specified purpose is required in order
to share personal health data, although there are exemptions for
specific situations. The possibilities are also dependent on national
laws that may provide exemptions or more specific interpretations
of the regulation; hence, implications may differ from one country
to another. It is expected that the implication of the GDPR and local
regulations on the possibilities to perform surveillance for quality
improvement and public health purposes will be clarified over the
coming years. Because of this complexity, early involvement of legal
specialists and data protection officers who understand the aims
that are pursued by the surveillance network regarding AS is
strongly recommended. As described earlier, there are multiple
possible designs for AS, with differences in the extent of data
sharing, level of aggregation and possibility for anonymization; in
addition, the choice for a design may be guided in part by the
possibilities available under relevant legislation.
Aside from complying with relevant regulations and technical
standards, the importance of pursuing trustworthiness from the
perception of the public as well as from participating healthcare
facilities cannot be emphasized enough. This should also include a
reflection on the ethical aspects of reusing medical data e fully
anonymized or not e for the purpose of surveillance healthcare
improvement. To ensure both confidence in adequate and confi-
dential data handling and trust in the surveillance results, adequate
communication and transparency with regard to the purpose of data
collection, data access and sharing are important. Achieving accep-
tance of the surveillance results requires monitoring, auditing and
validating methods and ensuring transparency. Further reading on
public trust, transparency, data protection and resources regarding
responsible data sharing can be found in the accompanying Gover-
nance article ([26]). Technical aspects of data sharing and security
are discussed in the IT article ([25] ‘Secured data transfer’).Validation of AS
Performance of AS can vary across different clinical settings and
patient populations, and it should undergo clinical and technical
validation in all contexts, where it will be used at initiation, peri-
odically after implementation and also when indicated as new
Table 7
Validation requirements, at initiation and periodically, with examples
Characteristic At initiation Periodically (yearly)
Correct extraction of source data Develop automated programming scripts to check
for inconsistencies; outlier handling, technical
validation.
Random sampling of data elements for manual
verification.
Manual verification of completeness by random
sampling.
Algorithm application Assessment of completeness of coding systems (e.g.
inclusion of relevant microbiologic results or
antibiotics).
Monitor for changes in coding systems or IT
updates.
Programming errors.
Algorithm performance Assessment of algorithm to correctly identify
patients with HAI (compare to reference
standard).
Manual validation of a random or targeted sample.
Agreement with clinical and documentation
practices.
Audit of changes in clinical practice.
Denominator calculation Correct application of inclusion and exclusion
criteria (compared to references).
Manual validation.
Calculation of device-days.
Data sharing with (and analysis by)
coordinating centre
Assessment integrity and completeness of data sent
to coordinating centre.
Periodic manual check of data integrity and
completeness.
Clinical acceptance Discussion with clinicians. Periodic discussion with clinicians.
Association with other outcomes, if deemed
relevant.
Associations with other outcomes.
Unless stated otherwise, these validation requirements apply to both locally and centrally implemented surveillance. Abbreviations: HAI, healthcare-associated infection; IT,
information technology.
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algorithms, denominator data and an assessment of the ability to
provide reliable benchmark data. Table 7 delineates elements
requiring validation; these apply both to locally and centrally
implemented surveillance, although the responsibility for the
different tasks may be implemented differently in each approach.
Validation of the source data includes technical validation to
assess completeness and inconsistencies ([25] ‘Technical data
validation’) as well as clinical validation to assess whether the
correct data have been extracted and whether the data are incor-
porated correctly in algorithms.
The performance of an algorithm is generally validated against a
reference standard; for example, conventional HAI surveillance is
based on manual chart review. Ideally, all diagnostic accuracy
markers derived from a 2  2 contingency table (sensitivity, spec-
ificity, PPV and negative predictive value) should be assessed using
a study design that avoids differential and partial verification bias
[74,75]. Overall accuracy is the ratio of all true predictions over all
predictions being made, but this is only useful if there are balanced
numbers of samples belonging to each group (HAI vs no HAI), and
the use of accuracy as a performance measure should usually be
avoided. The F score is the harmonic mean between sensitivity and
PPV, but it can be misleading and is not a sufficient measure for
assessing algorithm performance [76,77].
In some cases, there is insufficient reference data available to
allow for analysis of a 2  2 table, thus precluding a formal
assessment of sensitivity. For the sake of efficiency, some validation
studies then only consider the PPV as a marker of performance.
However, this approach is not recommended because it leaves
users uninformed regarding the true incidence of infections;
further, the sensitivity cannot be estimated because cases not
detected remain unrecorded. Alternative solutions to this challenge
include randomly sampling patients classified as high or low
probability (HAI/no HAI) with inverse probability weighting; or
applying a secondary reference standard to patients for whom
there is no reference standard available [74].
Similar to reliably identifying the target HAI, a reliable assess-
ment of the denominator data is paramount in order to obtain
comparable HAI incidence rates, both in locally and centrally
implemented surveillance. Whether deviations from manualassessment are acceptable will depend on the magnitude of the
error and the consequences for interpretation on the local and
network level. Importantly, manual counts of denominator data can
also contain errors, so a balanced assessment of acceptability is
warranted [47]. Particular aspects of denominator calculation that
can be difficult to automate include use of intravenous catheters or
other devices, as documentation can be poor and data are not al-
ways captured in a structured manner. Other challenges include
selection of the correct surgical procedure and application of
exclusion criteria (e.g. primary/nonprimary procedures and iden-
tification of preexisting infections) [47].
In both locally and centrally implemented AS, the coordinating
centre can facilitate appropriate validation by sharing validation
protocols, organizing top-down validation or peer-to-peer audits.
Specifically for semiautomated surveillance, ensuring adequate
validation of the case ascertainment by manual chart reviewe as is
currently also performed in conventional HAI surveillance e re-
mains essential.
Maintenance of the system
An established AS system needs ongoing maintenance and
further development activities, both in the participating healthcare
facilities and in the coordinating centre, in order to maintain data
quality and ensure acceptance of the system [20]. This requires the
allocation of sufficient resources. Depending on the number of
participating healthcare facilities and the number of HAI targeted,
the responsible team at the coordinating centre needs to include at
least one epidemiologist and at least one IT expert, although it may
also include other professionals such as microbiologists, IPC pro-
fessionals, pharmacologists or IT architects. In addition, superusers
may be appointed in local hospitals to validate data and perform
first-line troubleshooting. Resources should also be allocated for
the maintenance of servers, software licences and legal support.
Essential tasks that require ongoing maintenance are listed in
Table 8 [25].
Finally, throughout implementation, it is recommended that the
coordinating centre and participating healthcare facilities evaluate
whether the surveillance system provides meaningful data (e.g.
accurate, discriminating hospitals with good and bad
Table 9
Areas of future research
Topic Examples
Definitions and metrics Research into new case definitions suitable for AS.
Assess the acceptability of case definitions or surveillance targets.
Algorithms, denominator and
risk adjustment
Algorithms, also for use in specific settings (e.g. HAI associated with short admissions or specific patient populations).
Value of machine learning and artificial intelligence.
Value of specific data sources in AS.
Comparability between methods (manual or automated) and over time.
Methods for computing or estimating the denominator.
Methods of risk adjustment for new metrics.
Implementation aspects Strategies for successful deployment (e.g. top-down or bottom-up).
Definition of minimum viable products and minimum IT standards.
Impact assessment Acceptance of HAI rates generated by different AS methods by stakeholders, including healthcare providers and patients.
Assessment of the efficacy of data generated by AS in reducing HAI rates or other outcome measures (length of stay, mortality).
Assessment of the feedback process to guide change.
Opportunities to use the outcome of AS for other purposes (e.g. research).
Costebenefit assessment Workload reduction achieved by AS and changes in human resources required.
Costebenefit assessment of automated surveillance compared to conventional surveillance.
Abbreviations: AS, automated surveillance; HAI, healthcare-associated infection.
Table 8
Tasks to perform during the maintenance phase of AS operation
Task during maintenance phase Coordinating centre Participating healthcare facility
Maintain contact with relevant (clinical) stakeholders ✓ ✓
Train data users (including health authorities) to avoid misleading conclusions ✓
Change management: Adapt to changes in clinical practice, stakeholder preferences or legislation ✓ ✓
IT governance: Adapt to changes in EHRs, hospital IT systems or IT standards
(including interoperability and security)
✓ ✓
Coordinate improvements ✓
Perform and/or support validation of source data collection and algorithms ✓ ✓
Keep governance and legal issues up to date ✓ ✓
Offer IT support to participating healthcare facilities (incident management) ✓
Offer epidemiologic support to participating facilities ✓
Train new staff in participating healthcare facilities ✓ ✓
Abbreviations: AS, automated surveillance; EHRs, electronic health records; IT, information technology.
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to drive improvement. Depending on the number of participants,
this assessment could be performed yearly at the outset, then, for
example, every 3 years during the later phase.Areas of future research
Transitioning to AS entails moving away from conventional HAI
surveillance methods, and thus research is needed to optimize
surveillance methods and ensure acceptance among stakeholders.
Although the use of AS in individual hospitals has been scientifi-
cally evaluated, its impact when transitioning to large-scale sur-
veillance can only be assessed after the transition has started.
Therefore, studies must be done during piloting phases as well as
after implementation. Ideally, implementation efforts should be
linked to scientific evaluation from the outset in order to efficiently
collect the required information. Research topics requiring evalu-
ating are summarized in Table 9.Future steps
Transitions to large-scale AS will require the redevelopment of
surveillance methods, intensive dialogue with stakeholders and
considerable investment in resources. In order to truly implement
AS, future steps include translating this roadmap to the local situ-
ation and designing the most suitable approach to AS. This also
includes creating practical guidance checklists that can be used by
coordinating centres and healthcare facilities in the process of
implementing AS. In addition, dissemination and knowledgebuilding in IPC with respect to AS is necessary, along with
addressing the areas of future research and the updating of this
roadmap as the field evolves, in parallel with the progress of IT.Transparency declaration
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